GOSS — Gossamer Bio, Inc.

Gossamer Bio Q1 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: Gossamer ended Q1 2025 with $257.9 million in cash and cash equivalents, sufficient to fund operations through the first half of 2027.
• Revenue: Recognized revenue for the quarter was $9.9 million, primarily from collaboration with Chiesi, which included $6.6 million in cost reimbursements.
• Expenses:
  • R&D expenses increased to $38 million from $32.4 million year-over-year.
  • G&A expenses decreased to $8.7 million from $9.6 million year-over-year.
• Net Loss: The net loss for the quarter was $36.6 million, or $0.16 per share, an improvement from a net loss of $41.9 million, or $0.19 per share, in Q1 2024.

2. Strategic Updates and Business Highlights

• Seralutinib Development: Significant progress in the Phase III PROSERA study for Seralutinib, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension-associated interstitial lung disease (PH-ILD). Enrollment for new patient screenings has closed, with 343 patients currently enrolled and expected to complete enrollment by early June 2025.
• Patient Characteristics: The enrolled patient population shows promising baseline characteristics, including a higher proportion of functional Class III patients, which is expected to enhance the likelihood of positive treatment outcomes.
• PH-ILD Study: A Phase III SERANATA study for PH-ILD is set to begin site activations in Q4 2025, with a focus on a dual mechanism of action targeting both pulmonary hypertension and underlying lung fibrosis.

3. Forward Guidance and Outlook

• Data Timeline: Top-line results from the PROSERA study are anticipated in February 2026, following the completion of the blinded portion of the study.
• Market Potential: Gossamer aims to position Seralutinib as a first-in-class treatment for PAH and a potential backbone therapy, with significant commercial opportunities in both the U.S. and international markets, particularly Japan.

4. Bad News, Challenges, or Points of Concern

• Enrollment Challenges: The stringent enrollment criteria for the PROSERA study contributed to a longer-than-expected enrollment period, although the company remains committed to quality over speed.
• Competitive Landscape: The presence of existing therapies like sotatercept poses competitive pressures, particularly as Gossamer seeks to differentiate Seralutinib based on its safety profile and potential for long-term efficacy.
• Regulatory Uncertainties: While the FDA has agreed to the powering assumptions for the studies, there remains uncertainty regarding the specific thresholds for six-minute walk improvements necessary for approval.

5. Notable Q&A Insights

• Enrollment Strategy: Management emphasized the importance of enrolling the right patient population and the commitment to honor the trust of patients and physicians, which influenced the decision to continue with additional screenings.
• Combination Therapy Potential: There is interest in the potential for using Seralutinib in combination with existing therapies like sotatercept, although only a small number of patients on sotatercept are expected to qualify for the PROSERA study.
• Commercial Positioning: The company anticipates a market reset upon Seralutinib's launch, with a significant portion of patients having previously tried and potentially discontinued sotatercept, creating an opportunity for Seralutinib to capture a large share of the market.

Overall, Gossamer Bio is making substantial progress in its clinical trials and maintains a strong financial position, while navigating competitive and regulatory challenges in the evolving landscape of pulmonary hypertension therapies.